Immunocore, Gadeta announce agreement to develop gamma delta TCR ImmTAC

Immunocore and Gadeta B.V announced that they will collaborate on the first gammadelta ImmTAC for solid tumors, including colorectal cancer. "Immunocore pioneered TCR therapy with the launch of KIMMTRAK and we continue to push the edge of TCR science, including researching non-HLA restricted TCR therapies, both internally and through collaborations that complement our platform," said David Berman, Head of Research and Development of Immunocore. "We are very pleased to collaborate with Gadeta to combine their expertise in gamma delta TCRs with our scientific, development, and commercialization capabilities to deliver new TCR therapies." Under the terms of the agreement, Immunocore and Gadeta will collaborate on ‘201 gammadelta-TCR target discovery, and Immunocore will have the option to develop ImmTAC therapies derived from the ‘201 TCR as part of the research collaboration. Immunocore has an option for an exclusive license to further research, develop and commercialize an ImmTAC candidate from the collaboration. Gadeta is eligible to receive upfront, near-term option fee and research milestone payments.